Clontech Laboratories and TET Systems Announce the Broadening of their License Agreement
Complete the form below to unlock access to ALL audio articles.
Under the expanded license agreement, Clontech obtains rights to develop, manufacture and commercialize novel Tet Systems products as the Tet-On® 3G™ Inducible Expression System.
The Tet-On 3G Inducible Expression System provides highly inducible, sensitive control of gene expression. It includes two novel components, the rights to which were acquired by TET in 2009: (i) an improved transcriptional activator developed by scientists at the Academic Medical Center at the University of Amsterdam (AMC) in the Netherlands, and (ii) a novel minimal Tet promoter developed at the University of Heidelberg in Germany.
The Tet-System currently marketed by Clontech is already the gold standard for regulated gene expression, as measured by more than 7,000 peer-reviewed scientific publications. The new Tet-On 3G Inducible Expression System offers researchers even greater control of gene regulation due to lower expression in the non-induced state, even in transient transfection settings. The system’s ten-fold increased sensitivity for the inducing agent (Doxycycline) will also expand the long-established benefits of dynamic transactivation, particularly for in vivo models.
Carol Lou, General Manager of Clontech Laboratories, Inc., comments: “Clontech has a long history of leadership in developing technologies for gene delivery and expression, and a long-standing partnership with TET Systems. We are pleased to continue and extend this history by adding the Tet-On 3G Inducible Expression System to our portfolio of Tet System Products, which also includes our inducible Lenti-X™ systems.”
Clontech is launching a broad suite of Tet-On 3G Inducible Expression Systems, including different promoters, fluorescent markers, and bicistronic systems, which will be available August 2nd, 2010.